ValuEngine Downgrades Celldex Therapeutics (NASDAQ:CLDX) to Hold

ValuEngine cut shares of Celldex Therapeutics (NASDAQ:CLDX) from a buy rating to a hold rating in a report published on Thursday, ValuEngine reports.

Several other brokerages also recently weighed in on CLDX. Zacks Investment Research raised shares of Celldex Therapeutics from a sell rating to a hold rating in a research report on Friday, May 24th. HC Wainwright set a $19.00 target price on shares of Celldex Therapeutics and gave the stock a buy rating in a research report on Wednesday, May 8th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of Hold and an average price target of $12.38.

Shares of CLDX opened at $2.09 on Thursday. The company has a market capitalization of $28.78 million, a P/E ratio of -0.31 and a beta of 3.63. The company has a quick ratio of 7.41, a current ratio of 7.41 and a debt-to-equity ratio of 0.02. The firm’s 50 day moving average price is $2.50. Celldex Therapeutics has a twelve month low of $2.03 and a twelve month high of $11.63.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.14) by $0.01. The company had revenue of $1.43 million during the quarter, compared to the consensus estimate of $1.26 million. Celldex Therapeutics had a negative net margin of 729.59% and a negative return on equity of 45.09%. As a group, equities analysts predict that Celldex Therapeutics will post -4.8 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of the stock. Wedbush Securities Inc. purchased a new stake in Celldex Therapeutics during the second quarter valued at approximately $36,000. Virtu Financial LLC lifted its position in Celldex Therapeutics by 72.2% during the first quarter. Virtu Financial LLC now owns 25,826 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 10,825 shares during the last quarter. Geode Capital Management LLC lifted its position in Celldex Therapeutics by 9.0% during the fourth quarter. Geode Capital Management LLC now owns 1,119,913 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 92,792 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in Celldex Therapeutics by 1.5% during the fourth quarter. Two Sigma Investments LP now owns 1,741,075 shares of the biopharmaceutical company’s stock valued at $345,000 after acquiring an additional 25,859 shares during the last quarter. Institutional investors own 20.87% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

See Also: Blockchain

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.